Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945 on ClinicalTrials.gov · last registry update 2024-01-24

A small phase 3 — 26 participants, against a typical 424. The sponsor logged completion for December 2015. Primary outcome, as filed: Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University at Buffalo
Sponsor type: Other
Enrollment: 26
Started: 2015-08
Primary completion: 2015-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.

Conditions studied

Type 1 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.